What are the mechanisms, recommended dosing, and target‑controlled infusion (TCI) parameters for opioids in anesthesia, acute postoperative pain, and chronic pain management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Opioids in Anaesthesia, Chronic and Acute Pain: Mechanisms, Dosing, and TCI Infusions

For acute postoperative pain, prioritize nonopioid therapies first, and when opioids are necessary, use immediate-release formulations at the lowest effective dose for the shortest duration—typically no longer than needed for severe pain, with TCI systems offering superior control when available. 1

Mechanism of Action

Opioids work by binding to μ-opioid receptors in the central and peripheral nervous systems, inhibiting pain transmission and modulating pain perception. This receptor activation leads to analgesia but also produces side effects including respiratory depression, sedation, nausea, pruritus, and urinary retention.

Clinical Decision Algorithm for Opioid Use

Acute Pain Management (< 1 month)

Step 1: Maximize nonopioid therapies first 1

  • Nonopioid pharmacologic agents (NSAIDs, acetaminophen) and nonpharmacologic modalities (ice, heat, elevation, immobilization) are at least as effective as opioids for:
    • Low back pain
    • Neck pain
    • Musculoskeletal injuries (sprains, strains, tendonitis)
    • Minor surgeries with minimal tissue injury
    • Dental pain
    • Kidney stones
    • Headaches/migraine

Step 2: Reserve opioids for specific indications 1

  • Use opioids only when benefits clearly outweigh risks:
    • Severe traumatic injuries (crush injuries, burns)
    • Invasive surgeries with moderate-to-severe expected postoperative pain
    • When NSAIDs/other therapies are contraindicated or ineffective

Step 3: Prescribe appropriately when indicated 1

  • Immediate-release formulations only (never extended-release for acute pain)
  • Prescribe "as needed" (e.g., hydrocodone 5 mg/acetaminophen 325 mg, one tablet every 4 hours PRN) rather than scheduled dosing
  • Duration: Only for the expected duration of severe pain requiring opioids
  • Taper: If opioids used around-the-clock for >few days, implement taper to prevent withdrawal

Perioperative Pain Management

Regional anesthesia techniques should be prioritized as they reduce both acute pain and chronic postsurgical pain development 2, 3:

Neuraxial (Central Regional) Opioid Analgesia:

  • Epidural morphine provides superior pain relief compared to intramuscular morphine, with increased pruritus risk 2
  • Intrathecal morphine (preincisional or postincisional) demonstrates improved analgesia versus systemic routes 2
  • Epidural sufentanil and fentanyl show variable efficacy compared to IV routes 2

Patient-Controlled Analgesia (PCA):

  • Standard PCA with systemic opioids is effective but produces large plasma concentration variations 4

Chronic Pain Management (> 3 months)

Critical consideration: Patients with chronic pain on long-term opioids present unique challenges including tolerance, physical dependence, and opioid-induced hyperalgesia 5. For these patients:

  • Continue baseline opioid regimen perioperatively
  • Use nonopioid analgesics for additional acute pain when possible
  • If additional opioids required, use only for duration of severe acute pain, then return to baseline dosage 1
  • Consider opioid rotation to decrease requirements and improve effectiveness 5

Target-Controlled Infusion (TCI) Parameters

TCI systems provide superior pharmacokinetic control by automatically adjusting infusion rates to maintain desired target concentrations, creating more stable blood levels than traditional infusions or PCA. 4

Remifentanil TCI

Intraoperative use:

  • Effect-site concentrations typically 2-8 ng/mL depending on surgical stimulus
  • Critical limitation: Ultra-short context-sensitive half-time requires transition strategy before emergence 6
  • Administer morphine 0.15 mg/kg IV 30 minutes before anticipated end of surgery when using remifentanil 6

Postoperative patient-maintained TCI:

  • Initial target: 0.2 ng/mL increments patient-controlled 7
  • Mean effective concentration: 2.02 ng/mL (95% CI 1.87-2.16) for VAS ≤3 7
  • Time to satisfactory analgesia: approximately 19 minutes 7
  • Safety profile: No hypoxemia episodes, lowest respiratory rate 9 breaths/min 7
  • Side effects: Nausea 26.6%, vomiting 10% 7

Sufentanil TCI

Intraoperative and transition:

  • Effect-site concentration of 0.25 ng/mL at extubation provides superior postoperative analgesia compared to remifentanil-morphine combination 6
  • Does not compromise extubation or recovery times 6
  • Significantly reduces time to first analgesic request (55 vs 11 minutes) and total morphine consumption in first 24 hours compared to remifentanil 6

Hydromorphone TCI-PCA

Postoperative application:

  • Plasma target concentrations: 0.8-10 ng/mL range (patient-controlled within this range) 8
  • Initial TCI: 1-2 ng/mL until extubation 8
  • Mean dose during TCI-PCA: 0.26 mg/h (range 0.07-0.93) 8
  • Mean maximum plasma target: 2.3 ng/mL (range 0.9-7.0) 8
  • EC50 for NRS ≤4: 4.1 ng/mL (95% CI 0.6-12.8) 8
  • Efficacy: 83% of assessments achieved NRS <5 with deep inspiration 8
  • Side effects: Nausea 30%, vomiting 9%, respiratory insufficiency 5% 8

Critical Pitfalls to Avoid

  1. Never use extended-release opioids for acute pain 1
  2. Avoid scheduled dosing for acute pain—prescribe PRN only 1
  3. Do not use remifentanil TCI without transition analgesia strategy—its ultra-short duration leaves patients in severe pain immediately post-infusion 6
  4. Do not abruptly discontinue opioids in chronic pain patients perioperatively—maintain baseline regimen 1, 5
  5. Recognize that moderate acute postoperative pain intensity predicts chronic postsurgical pain development—these patients require aggressive early intervention 9

Long-Term Outcomes

Regional anesthesia significantly reduces both prolonged opioid use (RR 0.48) and chronic postsurgical pain at 3 months (RR 0.74) and 6 months (RR 0.72) after surgery 10. This represents the strongest modifiable intervention for preventing chronic pain and persistent opioid use.

Risk factors for persistent postoperative opioid use include: substance use disorders, depression, preoperative chronic pain (especially back pain), and certain surgeries (total knee/hip arthroplasty, open cholecystectomy) 11. Identify these patients preoperatively for enhanced monitoring and multimodal analgesia strategies.

References

5
Research

A Practical Approach to Acute Postoperative Pain Management in Chronic Pain Patients.

Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses, 2020

Related Questions

What are the guidelines for Total Intravenous Anesthesia (TCI) anesthesia?
What is the role of hydromorphone in postoperative pain management?
What is the dosing protocol for a Dilaudid (Hydromorphone) patient-controlled analgesia (PCA)?
What is the recommended dose of hydromorphone (opioid analgesic) for post-operative pain management at the end of a surgical case?
What anesthesia and postoperative pain management protocol is recommended for a red‑haired patient, given their tendency for higher opioid requirements?
What is the most appropriate next step to establish the diagnosis in a 23-year-old male with chronic difficulty falling asleep before 2 AM, excessive daytime sleepiness (Epworth Sleepiness Scale 16/24), well‑controlled obstructive sleep apnea on continuous positive airway pressure (CPAP), and 14 days of wearable actigraphy data?
What is the recommended dosage, duration, and contraindications for using diosmin after hemorrhoidectomy?
For a 55-year-old woman hospitalized with worsening dyspnea, left ventricular ejection fraction 30%, BNP 1100 pg/mL, non‑obstructive coronary disease, and troponin 38 pg/mL, which of the following is part of guideline‑directed medical therapy for heart failure with reduced ejection fraction: a glucagon‑like peptide‑1 receptor agonist, a vasodilator, a sodium‑glucose cotransporter‑2 inhibitor, or a calcium‑channel blocker?
In a 60-year-old woman with recent antibiotic treatment for a urinary tract infection, on methotrexate for rheumatoid arthritis and warfarin for atrial fibrillation, presenting with a week of increasing watery non‑bloody diarrhea, lower abdominal cramping, mild diffuse tenderness, anemia, leukocytosis, impaired renal function, and elevated C‑reactive protein, which diagnosis is most likely: ischemic colitis, inflammatory bowel disease, microscopic colitis, or Clostridioides difficile colitis?
What is the appropriate management and evaluation strategy for chronic pyelonephritis with urine cultures persistently growing multidrug‑resistant Klebsiella pneumoniae that is only susceptible to tigecycline and colistin?
What is the recommended target‑controlled infusion (TCI) protocol for remifentanil during anesthesia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question